The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's ...
Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve ...
Merck and Japan-based Eisai said on Friday a combination of their therapies failed to extend the lives of patients with a ...
GlobalData on MSN1d
Eisai and Biogen’s Leqembi sBLA set for Alzheimer’s maintenance dosingThe FDA has approved the sBLA of Eisai and Biogen's LEQEMBI for maintenance dosing indicated for the early stages of ...
GlobalData on MSN4d
MSD and Eisai’s LEAP gastroesophageal cancer trial sees mixed successMSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but ...
Eisai and Biogen have secured US Food and Drug Administration approval for a once-monthly intravenous maintenance dosing ...
The monthly maintenance regimen, which offers a more convenient frequency than the initially approved treatment schedule for ...
This article highlights recent developments in healthcare, including the U.S. FDA's approval of Alzheimer's and diabetes ...
Biogen and Eisai’s Alzheimer’s disease (AD) drug Leqembi (lecanemab-irmb) has been approved by the US Food and Drug ...
The Japanese and American based pharma companies announced a win for their Alzheimer’s treatment, which has faced some negative backlash over the last year.
The FDA approved a monthly maintenance dosing of intravenous lecanemab (Leqembi) for early Alzheimer's disease, said ...
Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback